The medical company is now valued at $1.4 billion.
The medical technology company HeartFlow is now valued at over $1 billion, the latest company to hit the category threshold for the most highly valued startups.
HeartFlow is expected to collect $150 million in a new fundraising round, according to a new regulatory filing in Delaware uncovered by PitchBook. At a price of about $25.33 per share, HeartFlow will have a valuation of $1.4 billion.
